- Novo’s second-quarter EBIT is reported at DKK 33.45 billion, falling short of the expected DKK 34.45 billion.
- Net income is DKK 26.50 billion, while the estimate was DKK 27.01 billion.
- The company’s gross margin stands at 83.3%, aligning with the estimate.
- Operating margin is slightly under expectations at 43.5%, compared to the estimated 44.2%.
- Sales and distribution costs are DKK 17.53 billion, higher than the anticipated DKK 16.82 billion.
- Pretax profit reaches DKK 33.81 billion, below the expected DKK 34.56 billion.
- GLP-1 sales are reported at DKK 38.37 billion but fall short of the projected DKK 39.45 billion.
- Sales of long-acting insulin are significantly below estimates at DKK 4.47 billion.
- Fast-acting insulin sales exceed expectations, coming in at DKK 4.54 billion.
- Total sales for diabetes and obesity care are DKK 71.94 billion, under the expected DKK 73.04 billion.
- Rare disease unit sales outperform estimates, totaling DKK 4.92 billion.
- Novo maintains its year forecast for sales growth at 8% to 14% on a constant exchange rate basis, below the estimate of 15.4%.
- Operating profit growth is also maintained at 10% to 16% at constant FX rates.
- CEO Lars Fruergaard Jørgensen mentions a lowered full-year outlook due to reduced growth expectations for GLP-1 treatments.
- Novo is focusing on enhancing commercial execution and ensuring cost efficiency while investing in future growth opportunities.
A look at Novo Nordisk A/S Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Novo Nordisk A/S, a pharmaceutical company known for its focus on diabetes care, has received favorable scores in key factors according to Smartkarma Smart Scores. With strong ratings in Dividend, Growth, Resilience, and Momentum, the company appears well-positioned for the long term. While its Value score is moderate, Novo Nordisk’s high marks in Dividend, Growth, and Resilience indicate a positive outlook for investors seeking stable returns and potential growth opportunities.
Specializing in insulin delivery systems and other diabetes products, Novo Nordisk also operates in haemostatis management, growth disorders, and hormone replacement therapy. The company’s commitment to providing educational resources alongside its pharmaceutical offerings underscores its dedication to addressing diverse healthcare needs worldwide. Considering its overall Smart Scores, Novo Nordisk A/S seems poised for continued success in the pharmaceutical industry, particularly in the areas of dividend payouts, growth potential, resilience, and maintaining momentum.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
